Modulating the Expression of Disease Genes with RNA-Based Therapy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
onventional gene therapy has focused largely on gene replacement in target cells.However, progress from basic research to the clinic has been slow for reasons relating principally to the challenges of heterologous DNA delivery and regulation in vivo.Alternative approaches targeting RNA have the potential to circumvent some of these difficulties, particularly as the active therapeutic molecules are usually short oligonucleotides and the target gene transcript is under endogenous regulation.RNA-based strategies offer a series of novel therapeutic applications, including altered processing of the target pre-mRNA transcript, reprogramming of genetic defects through mRNA repair, and the targeted silencing of allele-or isoform-specific gene transcripts.This review examines the potential of RNA therapeutics, focusing on antisense oligonucleotide modification of pre-mRNA splicing, methods for pre-mRNA trans-splicing, and the isoform-and allele-specific applications of RNA interference. Antisense Oligonucleotide-Based Manipulation of Pre-mRNA SplicingTraditionally, antisense oligonucleotides (AOs) have been employed to down-regulate gene transcription, through either RNase-H mediated degradation or steric blockage of gene promoter elements.More recently however, the potential of using AOs to alter pre-mRNA processing is being realised.Through utilisation of AO chemistries that do not induce transcript degradation, targeted blockage of motifs involved in splicing allows the manipulation of this process.Given that in the Human Gene Mutation Database (http:// www.hgmd.cf.ac.uk/ac/index.php);10% of annotated mutations impinge on splice sites [1], there is the potential for this approach to be applied to diseases caused by aberrant splicing, or where alteration of normal splicing would abrogate the disease-causing mutation.This could include: (i) blockage of cryptic splice sites, (ii) exon removal or inclusion to alter isoform expression, and (iii) removal of exons to either eliminate a nonsense mutation or restore the reading frame around a genomic deletion.Blockage of cryptic splicing.The concept of using AOs to alter pre-mRNA splicing was first demonstrated in bthalassemia, which is caused by mutations in the human bglobin gene [2].The most prevalent disease-causing mutations disrupt splicing of introns 1 and 2 of the b-globin pre-mRNA transcript through activation of cryptic splice sites, preventing production and translation of the correct mRNA [3].Blockage of these cryptic splice sites with AOs in erythroid cells abrogates their use, restoring normal globin expression [4] (Figure 1A).Similarly, in Hutchinson-Gilford progeria syndrome, a point mutation in exon 11 of the lamin A/C (LMNA) gene causes a silent substitution (GGCfiGGT) that results in activation of a cryptic donor splice site [5].Splicing between this cryptic splice site and the acceptor splice site gives rise to a truncated LMNA mRNA containing a
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes
Matranga, C., Tomari, Y., Shin, C., Bartel, D. P., & Zamore, P. D. (2005) · Cell · doi:10.1016/j.cell.2005.08.044 · Cited by 1,211
Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682 · cited 1×
“]. There is strong evidence to indicate that silencing the mutant allele in the most common polyglutamine disease, Huntington disease, is likely to be feasible in vivo and of therapeutic value [”
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564
Tolerance for mutations and chemical modifications in a siRNA
Amarzguioui, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg147 · Cited by 534
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Andreadis, A. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.010 · Cited by 311
Wu, J. Y., Kar, A., Kuo, D., Yu, B., & Havlioglu, N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00739-06 · Cited by 64
Cited by
Alternative splicing and evolution: diversification, exon definition and function
Keren, H., Lev-Maor, G., & Ast, G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2776 · Cited by 1,082
“Due to these advances, the regulation of AS is being widely used in gene therapy, revealing new therapeutic target”
BackgroundLong non-coding RNAs in nervous system function and disease
Qureshi, I. A., Mattick, J. S., & Mehler, M. F. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.110 · Cited by 430
Epigenetic principles and mechanisms underlying nervous system functions in health and disease
MEHLER, M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.10.001 · Cited by 291
Pennuto, M., Tinelli, E., Malaguti, M., Del Carro, U., D'Antonio, M., Ron, D., Quattrini, A., Feltri, M. L., & Wrabetz, L. (2008) · Neuron · doi:10.1016/j.neuron.2007.12.021 · Cited by 265
Spinal muscular atrophy: mechanisms and therapeutic strategies
Lorson, C. L., Rindt, H., & Shababi, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq147 · Cited by 209
Metadata
- Authors
- Wood, M., Yin, H., & McClorey, G.
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-06-29
- Volume
- 3
- Issue
- 6
- Pages
- e109
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- OpenAlex
- W2156670191
- Cited by
- 98
- References
- 8
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.